Metis Global Partners LLC Increases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Posted by Defense World Staff on Aug 13th, 2023

Metis Global Partners LLC grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 47.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,562 shares of the medical research company’s stock after purchasing an additional 505 shares during the quarter. Metis Global Partners LLC’s holdings in Charles River Laboratories International were worth $315,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in CRL. Texas Permanent School Fund raised its position in Charles River Laboratories International by 0.6% in the fourth quarter. Texas Permanent School Fund now owns 7,045 shares of the medical research company’s stock worth $1,535,000 after acquiring an additional 41 shares during the period. Wetherby Asset Management Inc. raised its holdings in Charles River Laboratories International by 2.5% in the 1st quarter. Wetherby Asset Management Inc. now owns 1,793 shares of the medical research company’s stock worth $509,000 after purchasing an additional 44 shares during the period. Future Fund LLC raised its holdings in Charles River Laboratories International by 3.7% in the 4th quarter. Future Fund LLC now owns 1,462 shares of the medical research company’s stock worth $319,000 after purchasing an additional 52 shares during the period. Toroso Investments LLC raised its holdings in Charles River Laboratories International by 4.8% in the 3rd quarter. Toroso Investments LLC now owns 1,141 shares of the medical research company’s stock worth $225,000 after purchasing an additional 52 shares during the period. Finally, New Hampshire Trust raised its holdings in Charles River Laboratories International by 10.4% in the 1st quarter. New Hampshire Trust now owns 572 shares of the medical research company’s stock worth $115,000 after purchasing an additional 54 shares during the period. Institutional investors own 98.55% of the company’s stock.

Analyst Ratings Changes

CRL has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their target price on Charles River Laboratories International from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Thursday. Credit Suisse Group decreased their target price on Charles River Laboratories International from $260.00 to $255.00 in a report on Friday, May 12th. Deutsche Bank Aktiengesellschaft decreased their target price on Charles River Laboratories International from $260.00 to $250.00 in a report on Friday, May 12th. StockNews.com assumed coverage on Charles River Laboratories International in a report on Thursday, May 18th. They set a “hold” rating on the stock. Finally, Wells Fargo & Company decreased their price target on Charles River Laboratories International from $290.00 to $280.00 in a report on Friday, May 12th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average target price of $247.80.

View Our Latest Analysis on CRL

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 345 shares of Charles River Laboratories International stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $190.39, for a total value of $65,684.55. Following the completion of the transaction, the executive vice president now owns 24,026 shares in the company, valued at $4,574,310.14. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Down 1.4 %

Shares of CRL stock opened at $214.46 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $181.22 and a 12-month high of $262.00. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.82. The stock’s 50-day moving average price is $207.38 and its 200-day moving average price is $209.70. The stock has a market capitalization of $11.00 billion, a price-to-earnings ratio of 22.74, a price-to-earnings-growth ratio of 1.48 and a beta of 1.33.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its earnings results on Wednesday, August 9th. The medical research company reported $2.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.06. Charles River Laboratories International had a return on equity of 18.99% and a net margin of 11.58%. The firm had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the previous year, the firm posted $2.77 earnings per share. The business’s revenue was up 8.9% compared to the same quarter last year. Equities research analysts predict that Charles River Laboratories International, Inc. will post 10.48 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

(Free Report)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).